Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) (INCYTOB)
Behcet's Disease, Panuveitis, Posterior Uveitis
About this trial
This is an interventional treatment trial for Behcet's Disease focused on measuring Ocular Behcet's disease, Panuveitis, Posterior Uveitis, Retinal vasculitis, Treatment, Interferon-alpha, Cyclosporin A
Eligibility Criteria
Inclusion Criteria: Behçet's disease fulfilling the International Study Group Criteria with active pan- or posterior uveitis (according to the posterior uveitis scoring system) or retinal vasculitis and active disease according to the Behcet's Disease activity scoring system. Exclusion Criteria: Previous treatment with interferon-α or cyclosporin A Pregnancy, breast feeding women, malignancy Renal impairment (creatinine > 1.5 mg/dl) Uncontrolled hypertension or diabetes Depression or other psychic disorders(also history of depression) History of acute or chronic inflammatory joint or autoimmune disease Organ or bone marrow transplant recipient, cardiac failure > NYHAIII Acute liver disease with SGPT 2x above normal White blood cell count < 3500/mm3 Platelet count < 100000/mm3 Hgb < 8.5g/dl Body weight <45 kg Alcohol abuse or drug abuse Mental impairment Uncooperative attitude
Sites / Locations
- Department of Internal Medicine II and Department of Ophthalmology
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
A Cyclosporin A
B Interferon alpha
Cyclosporin A
Interferon-alpha2a